JCAP vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JCAP presents a stark contrast between deep fundamental value and alarming insider behavior. While the Piotroski F-Score of 4/9 indicates stable health and the stock trades at a significant discount to its Graham Number ($32.19) and Intrinsic Value ($39.48), the technical trend is completely bearish. The company boasts an exceptional ROE of 43.78% and a very low P/E of 3.55, but these are overshadowed by massive insider selling totaling over $223M. Consequently, the valuation appeal is tempered by a lack of internal confidence and poor earnings surprise history.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
JCAP vs JPM: Head-to-Head Comparison
This page compares Jefferson Capital, Inc. (JCAP) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.